Opal Bio Pharma

SartoMax is honored to have supported Opal Bio Pharma (OBP) in advancing the growth of biopharmaceutical manufacturing in Oman. OBP has developed a cutting-edge single-use production platform based on CHO and baculovirus expression systems, enabling cost-effective and efficient development of biosimilar therapeutics and vaccines. This initiative enhances regional biomanufacturing capabilities and expands access to critical biologics.
As a leading CDMO, SartoMax has played a key role in streamlining OBP’s processes, scalability, and regulatory compliance. Our technical expertise has enabled OBP to optimize production efficiency and opens the potential to extend its reach beyond the GCC to the MENA region and other middle-income countries.